| By | 05/03/19

Impact of a Wireless “Wearable” Device to Measure Daily Activity in Patients With Coronary Microvascular Disease Treated With Late Na Channel Inhibition (ranolazine): a Substudy of the RWISE Clinical Trial

Fresh off the success of Fitbit’s Captivate roadshow, we’re bringing our keynote content to you on June 27th!

Join Fitbit’s medical director, Dr. John Moore, for an in-depth look at behavior change science and Fitbit's methodology. @john_o_moore https://t.co/FHTz8gnZu8

Calling all #SHRM19 Attendees: Come visit us at booth 1402 to see Fitbit Care in action!